FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000776349> ?p ?o ?g. }

• W2000776349 endingPage "166" @default.
• W2000776349 startingPage "160" @default.
• W2000776349 abstract "To determine whether there is a relationship between histologic subtype of epithelial ovarian cancer and chemoresistance, we evaluated ovarian carcinomas of six histologic subtypes and correlated histology with in vitro drug response. Biomarker profiles (p53, Her-2 neu, and EGFR) were also evaluated to determine if their expression patterns were associated with histology.In vitro drug response profiles for different histologic subsets of epithelial ovarian carcinomas exposed to standard relevant chemotherapy agents were determined in the Extreme Drug Resistance assay (EDR). Immunohistochemistry techniques were employed to determine biomarker expression.Of 5195 referred serial cases of epithelial ovarian cancer, there were 2660 papillary serous, 303 endometrioid, 142 mucinous, 102 clear cell, 952 undifferentiated carcinomas, and 42 tumors of low malignant potential. For the samples as a whole, the incidences of extreme drug resistance to the tested chemotherapeutic agents were cisplatin 10%, carboplatin 16%, cyclophosphamide 16%, doxorubicin 40%, gemcitabine 21%, paclitaxel 22%, and topotecan 13%. When compared to papillary serous tumors, mucinous tumors were more frequently resistant to cisplatin (10% vs. 18%) but less frequently resistant to topotecan (13% vs. 5%) and doxorubicin (42% vs. 16%). Endometrioid tumors were less resistant to cisplatin (10% vs. 6%) and doxorubicin (42% vs. 20%). Clear cell and undifferentiated tumors had the lowest rates of EDR to paclitaxel (13% and 18%) and cyclophosphamide (7% and 11%), while borderline tumors showed high rates of EDR to these agents (52% and 63%, respectively). With respect to biomarker profiles, mP53 was detected in 46%, Her-2 neu in 16%, and EGFR in 30% of the cases evaluated. As compared to all other subtypes, clear cell carcinomas had significantly higher Her-2 neu expression (19%). Relative to papillary serous carcinomas, borderline tumors exhibited significantly lower rates of mP53 expression (60% vs.17%).We found significant differences in the frequencies of extreme drug resistance to chemotherapeutic agents and biomarker expression among histologic subtypes of epithelial ovarian cancer. The data collected in this investigation may provide a guide for stratification of patients entering clinical trials based on histology and biomarker expression." @default.
• W2000776349 created "2016-06-24" @default.
• W2000776349 creator A5043157034 @default.
• W2000776349 creator A5057221032 @default.
• W2000776349 creator A5057396388 @default.
• W2000776349 creator A5061918246 @default.
• W2000776349 creator A5066909949 @default.
• W2000776349 date "2004-01-01" @default.
• W2000776349 modified "2023-09-26" @default.
• W2000776349 title "In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer" @default.
• W2000776349 cites W1544533071 @default.
• W2000776349 cites W1580547109 @default.
• W2000776349 cites W1827936231 @default.
• W2000776349 cites W1863225814 @default.
• W2000776349 cites W1882838018 @default.
• W2000776349 cites W1925884553 @default.
• W2000776349 cites W1966555965 @default.
• W2000776349 cites W1972085092 @default.
• W2000776349 cites W1972878967 @default.
• W2000776349 cites W1976748749 @default.
• W2000776349 cites W1982520097 @default.
• W2000776349 cites W1983414305 @default.
• W2000776349 cites W1994185611 @default.
• W2000776349 cites W1999044308 @default.
• W2000776349 cites W2001638605 @default.
• W2000776349 cites W2001877789 @default.
• W2000776349 cites W2017697346 @default.
• W2000776349 cites W2033748688 @default.
• W2000776349 cites W2044266510 @default.
• W2000776349 cites W2049883475 @default.
• W2000776349 cites W2075605944 @default.
• W2000776349 cites W2075908019 @default.
• W2000776349 cites W2077263403 @default.
• W2000776349 cites W2081027801 @default.
• W2000776349 cites W2108292279 @default.
• W2000776349 cites W2128818776 @default.
• W2000776349 cites W2128865543 @default.
• W2000776349 cites W2136776823 @default.
• W2000776349 cites W2151605875 @default.
• W2000776349 cites W2154486759 @default.
• W2000776349 cites W2155126523 @default.
• W2000776349 cites W2166310305 @default.
• W2000776349 cites W2168399386 @default.
• W2000776349 cites W2319830019 @default.
• W2000776349 cites W2328421677 @default.
• W2000776349 cites W2406997562 @default.
• W2000776349 cites W2408576355 @default.
• W2000776349 cites W2418275554 @default.
• W2000776349 cites W2439343438 @default.
• W2000776349 cites W2616518329 @default.
• W2000776349 cites W3181912078 @default.
• W2000776349 cites W71838081 @default.
• W2000776349 cites W84548433 @default.
• W2000776349 cites W2414613535 @default.
• W2000776349 doi "https://doi.org/10.1016/j.ygyno.2003.09.030" @default.
• W2000776349 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14751152" @default.
• W2000776349 hasPublicationYear "2004" @default.
• W2000776349 type Work @default.
• W2000776349 sameAs 2000776349 @default.
• W2000776349 citedByCount "56" @default.
• W2000776349 countsByYear W20007763492012 @default.
• W2000776349 countsByYear W20007763492013 @default.
• W2000776349 countsByYear W20007763492014 @default.
• W2000776349 countsByYear W20007763492016 @default.
• W2000776349 countsByYear W20007763492018 @default.
• W2000776349 countsByYear W20007763492019 @default.
• W2000776349 countsByYear W20007763492020 @default.
• W2000776349 countsByYear W20007763492021 @default.
• W2000776349 countsByYear W20007763492022 @default.
• W2000776349 countsByYear W20007763492023 @default.
• W2000776349 crossrefType "journal-article" @default.
• W2000776349 hasAuthorship W2000776349A5043157034 @default.
• W2000776349 hasAuthorship W2000776349A5057221032 @default.
• W2000776349 hasAuthorship W2000776349A5057396388 @default.
• W2000776349 hasAuthorship W2000776349A5061918246 @default.
• W2000776349 hasAuthorship W2000776349A5066909949 @default.
• W2000776349 hasConcept C121608353 @default.
• W2000776349 hasConcept C126322002 @default.
• W2000776349 hasConcept C142724271 @default.
• W2000776349 hasConcept C143998085 @default.
• W2000776349 hasConcept C150173356 @default.
• W2000776349 hasConcept C204232928 @default.
• W2000776349 hasConcept C2776694085 @default.
• W2000776349 hasConcept C2777292972 @default.
• W2000776349 hasConcept C2778239845 @default.
• W2000776349 hasConcept C2780258809 @default.
• W2000776349 hasConcept C2780427987 @default.
• W2000776349 hasConcept C2781197716 @default.
• W2000776349 hasConcept C2781209748 @default.
• W2000776349 hasConcept C2781303535 @default.
• W2000776349 hasConcept C2781451048 @default.
• W2000776349 hasConcept C502942594 @default.
• W2000776349 hasConcept C55493867 @default.
• W2000776349 hasConcept C71924100 @default.
• W2000776349 hasConcept C86803240 @default.
• W2000776349 hasConceptScore W2000776349C121608353 @default.
• W2000776349 hasConceptScore W2000776349C126322002 @default.
• W2000776349 hasConceptScore W2000776349C142724271 @default.

• next